Celularity and Fountain Life are offering placental-derived cell therapy (Cenplacel-L) for investigational use in Florida under a state statute permitting physician-directed access to non-FDA-approved cell therapies. The therapy targets inflammation and age-related degeneration, positioning allogeneic cell treatment as an emerging tool in preventive longevity medicine.
Key Points
- Placental-derived allogeneic cell therapy available for physician-directed use in Florida
- Targets inflammation, degeneration, and age-related disease processes
- Clinical-grade manufacturing enables systematic data collection on safety and efficacy
Longevity Analysis
Access to investigational cell therapies under state statute creates a pragmatic pathway for clinicians to gather real-world data on regenerative medicine's capacity to modulate inflammatory signaling and support tissue repair—mechanisms central to both disease prevention and aging. The integration of advanced diagnostics with physician oversight establishes a framework for understanding which patient phenotypes respond to cellular interventions, filling a critical gap between laboratory efficacy and clinical applicability. This model allows practitioners to decode inflammatory and degenerative signals while testing whether exogenous cellular support can shift systemic trajectory in aging populations.
Original published by LT Wire.